Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer : Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study - Van Cutsem, Eric (University Hospitals Gasthuisberg (Leuven, Bélgica)) ; Huijberts, Sanne (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ; Grothey, Axel (West Cancer Center, Germantown, TN) ; Yaeger, Rona (Memorial Sloan Kettering Cancer Center) ; Cuyle, Pieter-Jan (University Hospitals Gasthuisberg (Leuven, Bélgica)) ; Elez, Elena (Vall d'Hebron Institut d'Oncologia) ; Fakih, Marwan (City of Hope National Medical Center (Duarte, Estats Units d'Amèrica)) ; Montagut, Clara (Institut Hospital del Mar d'Investigacions Mèdiques) ; Peeters, Marc (University Hospital Antwerp (Bèlgica)) ; Yoshino, Takayuki (National Cancer Center Hospital East, Kashiwa, Japan) ; Wasan, Harpreet (Hammersmith Hospital (Londres)) ; Desai, Jayesh (Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia) ; Ciardiello, Fortunato (University of Campania "Luigi Vanvitelli" (Nàpols, Itàlia)) ; Gollerkeri, Ashwin (Array BioPharma Inc) ; Christy-Bittel, Janna (Array BioPharma Inc) ; Maharry, Kati (Array BioPharma Inc) ; Sandor, Victor (Array BioPharma Inc) ; Schellens, Jan H. M. (Utrecht University) ; Kopetz, Scott (The University of Texas MD Anderson Cancer Center, Houston, TX) ; Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ; Vall d'Hebron Institut de Recerca (VHIR)